These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25132340)

  • 1. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
    Leitner L; Walter M; Freund P; Mehnert U; Michels L; Kollias S; Kessler TM
    BMC Urol; 2014 Aug; 14():68. PubMed ID: 25132340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
    Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
    BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
    Khavari R; Elias SN; Pande R; Wu KM; Boone TB; Karmonik C
    J Urol; 2019 Jan; 201(1):135-140. PubMed ID: 30076906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
    Krhut J; Samal V; Nemec D; Zvara P
    Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
    Ferreira RS; D'Ancona CAL; Oelke M; Carneiro MR
    Einstein (Sao Paulo); 2018 Aug; 16(3):eAO4207. PubMed ID: 30088545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
    Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC; Kuo HC
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis.
    Elizondo RA; Karmonik C; Boone TB; Khavari R
    BMJ Open; 2017 Feb; 7(2):e013225. PubMed ID: 28159850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
    Chen SF; Chang CH; Kuo HC
    Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
    Alvares RA; Silva JA; Barboza AL; Monteiro RT
    Int Braz J Urol; 2010; 36(6):732-7. PubMed ID: 21176280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.
    Mailho C; Peyronnet B; De Seze M; Even A; Perrouin-Verbe MA; Amarenco G; Chartier-Kastler E; Le Normand L; Manunta A; Karsenty G; Kerdraon J; Ruffion A; Saussine C; Le Breton F; Bernuz B; Castel-Lacanal E; Denys P; Phé V; Gamé X
    Neurourol Urodyn; 2024 Apr; 43(4):811-817. PubMed ID: 38451038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of onabotulinumtoxinA on cardiac function following intradetrusor injections.
    Mehnert U; de Kort LM; Wöllner J; Kozomara M; van Koeveringe GA; Kessler TM
    Exp Neurol; 2016 Nov; 285(Pt B):167-172. PubMed ID: 27342082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.